Determination of human serum semicarbazide-sensitive amine oxidase activity

A possible clinical marker of atherosclerosis

Zsuza Mészáros, I. Karádi, A. Csányi, T. Szombathy, L. Romics, K. Magyar

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Semicarbazide-sensitive amine oxidase (SSAO) is present in the plasma membrane of several human tissues, e.g. vascular smooth muscle cell adipocytes, and is also found in human serum. Some previous studies on cultured endothelial cells indicate that cytotoxic metabolites (e.g. hydrogen peroxide, formaldehyde, acrolein) formed by serum SSAO may cause endothelial injury and subsequently induce atherosclerosis. To investigate the role of this enzyme in the pathogenesis of macrovascular complications in diabetes, a simple and sensitive radiometric procedure was adapted for human serum measurements. Serum SSAO activity of 35 patients with non-insulin dependent diabetes mellitus (NIDDM) and that of 30 controls was determined using [14C]-benzylamine as substrate. The severity of atherosclerosis was assessed by carotid sonography. Diabetic patients with atherosclerosis exhibited a higher SSAO activity compared to diabetic patients without complications (212.91 ± 90.54 pmol/mg protein/h versus 133.17 ± 65.40 pmol/mg protein/h, P <0.04). In diabetic patients without complications, serum SSAO activity was elevated compared to control subjects (133.17 ± 65.40 pmol/mg protein/h versus 91.79 ± 31.70 pmol/mg protein/h, P <0.01). These results suggest that determination of human serum SSAO activity might be a useful marker in the prognostic evaluation of diabetic angiopathy and atherosclerosis.

Original languageEnglish
Pages (from-to)299-302
Number of pages4
JournalEuropean Journal of Drug Metabolism and Pharmacokinetics
Volume24
Issue number4
Publication statusPublished - 1999

Fingerprint

Amine Oxidase (Copper-Containing)
Atherosclerosis
Biomarkers
Serum
Proteins
Acrolein
Diabetic Angiopathies
Diabetes Complications
Vascular Smooth Muscle
Adipocytes
Type 2 Diabetes Mellitus
Hydrogen Peroxide
Formaldehyde
Smooth Muscle Myocytes
Cultured Cells
Ultrasonography
Endothelial Cells
Cell Membrane
Wounds and Injuries
Enzymes

Keywords

  • Atherosclerosis
  • Risk factor
  • Semicarbazide-sensitive amine oxidase

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Determination of human serum semicarbazide-sensitive amine oxidase activity : A possible clinical marker of atherosclerosis. / Mészáros, Zsuza; Karádi, I.; Csányi, A.; Szombathy, T.; Romics, L.; Magyar, K.

In: European Journal of Drug Metabolism and Pharmacokinetics, Vol. 24, No. 4, 1999, p. 299-302.

Research output: Contribution to journalArticle

@article{098b21d80e34472496d18c820e556e70,
title = "Determination of human serum semicarbazide-sensitive amine oxidase activity: A possible clinical marker of atherosclerosis",
abstract = "Semicarbazide-sensitive amine oxidase (SSAO) is present in the plasma membrane of several human tissues, e.g. vascular smooth muscle cell adipocytes, and is also found in human serum. Some previous studies on cultured endothelial cells indicate that cytotoxic metabolites (e.g. hydrogen peroxide, formaldehyde, acrolein) formed by serum SSAO may cause endothelial injury and subsequently induce atherosclerosis. To investigate the role of this enzyme in the pathogenesis of macrovascular complications in diabetes, a simple and sensitive radiometric procedure was adapted for human serum measurements. Serum SSAO activity of 35 patients with non-insulin dependent diabetes mellitus (NIDDM) and that of 30 controls was determined using [14C]-benzylamine as substrate. The severity of atherosclerosis was assessed by carotid sonography. Diabetic patients with atherosclerosis exhibited a higher SSAO activity compared to diabetic patients without complications (212.91 ± 90.54 pmol/mg protein/h versus 133.17 ± 65.40 pmol/mg protein/h, P <0.04). In diabetic patients without complications, serum SSAO activity was elevated compared to control subjects (133.17 ± 65.40 pmol/mg protein/h versus 91.79 ± 31.70 pmol/mg protein/h, P <0.01). These results suggest that determination of human serum SSAO activity might be a useful marker in the prognostic evaluation of diabetic angiopathy and atherosclerosis.",
keywords = "Atherosclerosis, Risk factor, Semicarbazide-sensitive amine oxidase",
author = "Zsuza M{\'e}sz{\'a}ros and I. Kar{\'a}di and A. Cs{\'a}nyi and T. Szombathy and L. Romics and K. Magyar",
year = "1999",
language = "English",
volume = "24",
pages = "299--302",
journal = "European Journal of Drug Metabolism and Pharmacokinetics",
issn = "0378-7966",
publisher = "Springer Paris",
number = "4",

}

TY - JOUR

T1 - Determination of human serum semicarbazide-sensitive amine oxidase activity

T2 - A possible clinical marker of atherosclerosis

AU - Mészáros, Zsuza

AU - Karádi, I.

AU - Csányi, A.

AU - Szombathy, T.

AU - Romics, L.

AU - Magyar, K.

PY - 1999

Y1 - 1999

N2 - Semicarbazide-sensitive amine oxidase (SSAO) is present in the plasma membrane of several human tissues, e.g. vascular smooth muscle cell adipocytes, and is also found in human serum. Some previous studies on cultured endothelial cells indicate that cytotoxic metabolites (e.g. hydrogen peroxide, formaldehyde, acrolein) formed by serum SSAO may cause endothelial injury and subsequently induce atherosclerosis. To investigate the role of this enzyme in the pathogenesis of macrovascular complications in diabetes, a simple and sensitive radiometric procedure was adapted for human serum measurements. Serum SSAO activity of 35 patients with non-insulin dependent diabetes mellitus (NIDDM) and that of 30 controls was determined using [14C]-benzylamine as substrate. The severity of atherosclerosis was assessed by carotid sonography. Diabetic patients with atherosclerosis exhibited a higher SSAO activity compared to diabetic patients without complications (212.91 ± 90.54 pmol/mg protein/h versus 133.17 ± 65.40 pmol/mg protein/h, P <0.04). In diabetic patients without complications, serum SSAO activity was elevated compared to control subjects (133.17 ± 65.40 pmol/mg protein/h versus 91.79 ± 31.70 pmol/mg protein/h, P <0.01). These results suggest that determination of human serum SSAO activity might be a useful marker in the prognostic evaluation of diabetic angiopathy and atherosclerosis.

AB - Semicarbazide-sensitive amine oxidase (SSAO) is present in the plasma membrane of several human tissues, e.g. vascular smooth muscle cell adipocytes, and is also found in human serum. Some previous studies on cultured endothelial cells indicate that cytotoxic metabolites (e.g. hydrogen peroxide, formaldehyde, acrolein) formed by serum SSAO may cause endothelial injury and subsequently induce atherosclerosis. To investigate the role of this enzyme in the pathogenesis of macrovascular complications in diabetes, a simple and sensitive radiometric procedure was adapted for human serum measurements. Serum SSAO activity of 35 patients with non-insulin dependent diabetes mellitus (NIDDM) and that of 30 controls was determined using [14C]-benzylamine as substrate. The severity of atherosclerosis was assessed by carotid sonography. Diabetic patients with atherosclerosis exhibited a higher SSAO activity compared to diabetic patients without complications (212.91 ± 90.54 pmol/mg protein/h versus 133.17 ± 65.40 pmol/mg protein/h, P <0.04). In diabetic patients without complications, serum SSAO activity was elevated compared to control subjects (133.17 ± 65.40 pmol/mg protein/h versus 91.79 ± 31.70 pmol/mg protein/h, P <0.01). These results suggest that determination of human serum SSAO activity might be a useful marker in the prognostic evaluation of diabetic angiopathy and atherosclerosis.

KW - Atherosclerosis

KW - Risk factor

KW - Semicarbazide-sensitive amine oxidase

UR - http://www.scopus.com/inward/record.url?scp=0343183095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0343183095&partnerID=8YFLogxK

M3 - Article

VL - 24

SP - 299

EP - 302

JO - European Journal of Drug Metabolism and Pharmacokinetics

JF - European Journal of Drug Metabolism and Pharmacokinetics

SN - 0378-7966

IS - 4

ER -